Healthcare
Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study (GMCS)
Seegene Inc., a global molecular diagnostics company, announced a comprehensive syndromic PCR-based testing approach for reproductive tract infections (RTIs) through the simultaneous detection of sexually transmitted infections (STIs) and human papillomavirus (HPV).
About this update from Seegene, Inc.
SEOUL, South Korea, July 27, 2026 /PRNewswire/ -- Seegene Inc., a global molecular diagnostics company, announced a comprehensive syndromic PCR-based testing approach for reproductive tract infections (RTIs) through the simultaneous detection of sexually transmitted infections (STIs) and human papillomavirus (HPV). The announcement follows Seegene's launch of the Global Million Clinical Study (GMCS) on July 8. The initiative aims to generate scientific evidence for Global New Standard of PCR testing by accumulating real-world clinical data from healthcare institutions worldwide and evaluating the clinical utility of disease-specific diagnostic testing strategies. HPV is widely recognized as the primary cause of cervical cancer, and certain high-risk genotypes, particularly HPV-16 and HPV-18, are closely associated with disease progression. Because screening and follow-up strategies may vary depending on the HPV genotype detected, identifying not only the presence of HPV but also the genotype provides important clinical information for patient management. STIs are caused by a variety of pathogens, including Chlamydia trachomatis and Neisseria gonorrhoeae. They may present with a broad range of symptoms, including abnormal discharge, dysuria, genital pain or itching, dyspareunia, lower abdominal pain, genital ulcers, vesicles or warts, and infertility. Because different pathogens often cause similar clinical symptoms, identifying the causative pathogen with symptoms alone may be difficult. In addition, asymptomatic infections are common and may contribute to unrecognized transmission. Recent studies have suggested that STIs and vaginal dysbiosis may be associated with changes in the local inflammatory, immune, and microbial environment of the cervix, potentially influencing HPV acquisition, persistence, or clearance. This growing body of evidence underscores the importance of interpreting HPV and STI findings within the broader clinical context – including the patient's age, symptoms, sexual history and exposure risk, pregnancy plan, prior infection history and the specific organism detected. Together, these findings provide a scientific rationale for further evaluating a comprehensive HPV and STI testing approach that assesses HPV risk alongside concurrent sexually transmitted and reproductive tract infections. Using STAgora™, Seegene's real-time test data...